Incyte Past Earnings Performance
Past criteria checks 1/6
Incyte has been growing earnings at an average annual rate of 16.9%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 12.5% per year. Incyte's return on equity is 1%, and it has net margins of 0.8%.
Key information
16.9%
Earnings growth rate
16.5%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 12.5% |
| Return on equity | 1.0% |
| Net Margin | 0.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,076 | 32 | 1,207 | 0 |
| 30 Jun 24 | 3,857 | 97 | 1,165 | 0 |
| 31 Mar 24 | 3,768 | 745 | 1,143 | 0 |
| 31 Dec 23 | 3,696 | 598 | 1,159 | 0 |
| 30 Sep 23 | 3,609 | 425 | 1,138 | 0 |
| 30 Jun 23 | 3,513 | 366 | 1,136 | 0 |
| 31 Mar 23 | 3,470 | 324 | 1,105 | 0 |
| 31 Dec 22 | 3,395 | 341 | 999 | 0 |
| 30 Sep 22 | 3,331 | 876 | 954 | 0 |
| 30 Jun 22 | 3,320 | 945 | 879 | 0 |
| 31 Mar 22 | 3,115 | 933 | 796 | 0 |
| 31 Dec 21 | 2,986 | 949 | 741 | 0 |
| 30 Sep 21 | 2,913 | 535 | 682 | 0 |
| 30 Jun 21 | 2,721 | 338 | 612 | 0 |
| 31 Mar 21 | 2,703 | 478 | 561 | 0 |
| 31 Dec 20 | 2,667 | -296 | 518 | 0 |
| 30 Sep 20 | 2,457 | -335 | 487 | 0 |
| 30 Jun 20 | 2,388 | -191 | 469 | 0 |
| 31 Mar 20 | 2,229 | -376 | 457 | 0 |
| 31 Dec 19 | 2,159 | 447 | 469 | 0 |
| 30 Sep 19 | 2,108 | 405 | 441 | 0 |
| 30 Jun 19 | 2,006 | 306 | 435 | 0 |
| 31 Mar 19 | 1,997 | 253 | 437 | 0 |
| 31 Dec 18 | 1,882 | 109 | 435 | 0 |
| 30 Sep 18 | 1,798 | -109 | 424 | 0 |
| 30 Jun 18 | 1,729 | -102 | 419 | 0 |
| 31 Mar 18 | 1,534 | -167 | 401 | 0 |
| 31 Dec 17 | 1,536 | -313 | 367 | 0 |
| 30 Sep 17 | 1,419 | -155 | 363 | 0 |
| 30 Jun 17 | 1,306 | -154 | 348 | 0 |
| 31 Mar 17 | 1,226 | -107 | 324 | 0 |
| 31 Dec 16 | 1,106 | 104 | 302 | 0 |
| 30 Sep 16 | 1,023 | 151 | 260 | 0 |
| 30 Jun 16 | 941 | 74 | 231 | 0 |
| 31 Mar 16 | 858 | 49 | 216 | 0 |
| 31 Dec 15 | 754 | 7 | 197 | 0 |
| 30 Sep 15 | 634 | -86 | 193 | 0 |
| 30 Jun 15 | 644 | 13 | 184 | 0 |
| 31 Mar 15 | 581 | -33 | 174 | 0 |
| 31 Dec 14 | 511 | -48 | 166 | 0 |
| 30 Sep 14 | 485 | -54 | 155 | 0 |
| 30 Jun 14 | 372 | -136 | 142 | 0 |
| 31 Mar 14 | 374 | -101 | 125 | 0 |
| 31 Dec 13 | 355 | -83 | 110 | 0 |
Quality Earnings: INCY * has a large one-off gain of $121.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: INCY *'s current net profit margins (0.8%) are lower than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INCY *'s earnings have grown by 16.9% per year over the past 5 years.
Accelerating Growth: INCY *'s has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INCY * had negative earnings growth (-92.4%) over the past year, making it difficult to compare to the Biotechs industry average (4%).
Return on Equity
High ROE: INCY *'s Return on Equity (1%) is considered low.